TG Therapeutics, Inc.
Here’s whether TG Therapeutics, Inc. (TGTX) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Neutral.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+2.68% over 10 days); 3-month momentum positive (+15.6%). Concerns: RSI 75 — overbought, elevated pullback risk; declining volume on rally — weak conviction (0.80x 30d avg). Currently 24.0% off its 52-week high. Score: +3/7.
TGTX is in a confirmed uptrend, trading above both its 50-day ($30.77) and 200-day ($31.95) moving averages. With an RSI of 75.0, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of -7.5% compares to +35.1% for SPY (trailed the market by 42.6%). The current 24.0% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.